Zhang Meng, Zhang Xiang, Wang Chunlan, Shen Yangfang, Fu Jianan
Department of Gynecological Radiation Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Emerg Med Int. 2022 Aug 24;2022:7806659. doi: 10.1155/2022/7806659. eCollection 2022.
To determine the role of Jinhuang Powder to prevent adverse effects of subcutaneous injection of enoxaparin sodium.
The clinical data of 97 patients with cervical cancer who were treated with subcutaneous injection of enoxaparin through the lower margin of the deltoid muscle of the upper arm in Zhejiang Tumor Hospital from August 2020 to August 2021 were retrospectively analyzed. All patients were divided into the control group ( = 39) and the research group ( = 58) according to the different use time periods of Jinhuang Powder. The research group was treated with Jinhuang Powder and enoxaparin sodium at the same time. The control group started to use Jinhuang Powder after the adverse reactions occurred. The induration, subcutaneous bleeding events, and pain were statistically analyzed.
The incidence of induration (3.4% vs 15.4%, =0.036) and subcutaneous hemorrhage (37.9% vs 76.9%, =0.003) in the research group was significantly lower than that in the control group. The pain in the research group was lighter than that in the control group (grade 0-4 pain: 70% vs 28.2%, 19% vs 30.8%, 8.6% vs 23.1%, 1.7% vs 12.8%, 1.7% vs 5.1%, =0.001).
Preventive use of Jinhuang Powder can significantly reduce the incidence of subcutaneous induration and subcutaneous bleeding and can effectively alleviate the local pain of injection. It is worthy of further study to clarify its role and mechanism.
探讨金黄散预防皮下注射低分子肝素钠不良反应的作用。
回顾性分析2020年8月至2021年8月在浙江省肿瘤医院行上臂三角肌下缘皮下注射低分子肝素钠治疗的97例宫颈癌患者的临床资料。根据金黄散使用时间段不同将所有患者分为对照组（n = 39）和研究组（n = 58）。研究组同时使用金黄散和低分子肝素钠，对照组在出现不良反应后开始使用金黄散。对硬结、皮下出血事件及疼痛情况进行统计学分析。
研究组硬结发生率（3.4% 对15.4%，P = 0.036）及皮下出血发生率（37.9% 对76.9%，P = 0.003）均显著低于对照组。研究组疼痛程度轻于对照组（0 - 4级疼痛：70% 对28.2%，19% 对30.8%，8.6% 对23.1%，1.7% 对12.8%，1.7% 对5.1%，P = 0.001）。
预防性使用金黄散可显著降低皮下硬结及皮下出血的发生率，并能有效减轻注射部位局部疼痛。其作用及机制有待进一步研究明确。
